Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.This is an entirely free service. No payments are to be made.
Here is the latest stock price and chart of SANJIVANI PA. For a sector overview, read our pharmaceuticals sector report.
|Live BSE Quotes||Apr 28, 2017 03:34:00 PM|
|Price (Rs)11.10||Open (Rs) 11.40||High (Rs) 11.96||Low (Rs) 11.00|
|% Change-2.72||Volume 23,253||Value (Rs) 258,108||52-Week H/L 36.40 / 10.58|
|Live NSE Quotes|
|BSE Sensex | CNX Nifty|
Indian share markets retreated in today's trade from record highs hit earlier this week as investors booked profits ahead of a long weekend.
Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.
Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.
Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.
Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.
Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.More Views on News
Rohan and Kunal present you the discussions with professor Sanjay Bakshi in his virtual classroom.
Why HDFC Bank beat the Sensex by nearly 3 times.
Are you excited to trade in the sixteen new stocks to be introduced in the F&O segment this Friday?
While it is important to get Mallya back to India, the government needs to show the same vigour in chasing defaulters of public sector bank loans residing in India.
PersonalFN explains how GST would impact India's mutual fund industry and investorsMore